Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background & Aims: We investigated the benefit-risk profile of aspirin on mortality reduction from chemoprevention of gastrointestinal (GI) cancer vs excess mortality from bleeding among Helicobacter pylori-eradicated patients, and its interaction with proton pump inhibitors (PPIs).
Methods: H pylori-eradicated patients (between 2003 and 2016), identified from a territory-wide database, were observed from the date of H pylori therapy until death or the end of the study (July 2020). Primary exposure was aspirin use as time-varying variable. The primary outcome was GI cancer-related (gastrointestinal, hepatobiliary, or pancreatic cancer) death and the secondary outcome was bleeding-related (gastrointestinal bleeding or intracranial bleeding) death. The adjusted hazard ratio (aHR) of outcomes was calculated by multivariable Cox model after adjusting for age, sex, comorbidities, and concomitant medications. The benefit-risk profile was expressed as the adjusted absolute risk difference of cancer-related deaths and bleeding-related deaths between aspirin users and nonusers.
Results: A total of 87,967 subjects were followed up for a median of 10.1 years, with 1294 (1.5%) GI cancer-related deaths and 304 (0.3%) bleeding-related deaths. Aspirin was associated with lower GI cancer-related mortality (aHR, 0.51; 95% CI, 0.42-0.61), but higher bleeding-related mortality (aHR, 1.52; 95% CI, 1.11-2.08). Among PPI users, the aHR of bleeding-related mortality with aspirin was 1.06 (95% CI, 0.70-1.63). For the whole cohort, the adjusted absolute risk difference between aspirin users and nonusers was 7 (95% CI, 5-8) fewer cancer-related and 1 (95% CI, 0.3-3) more bleeding-related death per 10,000 person-years. Among concomitant PPI-aspirin use, there were 9 (95% CI, 8-10) fewer cancer-related deaths per 10,000 person-years without an increase in bleeding-related deaths.
Conclusions: GI cancer mortality benefit from aspirin outweighs bleeding-related mortality in H pylori-eradicated subjects, which is enhanced further by PPI use.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.cgh.2024.05.003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Development and Validation of the Early Gastric Carcinoma Prediction Model in Post-Eradication Patients with Intestinal Metaplasia.
Cancers (Basel)
June 2025
Fuzong Clinical Medical College of Fujian Medical University, Fuzhou 350005, China.
: Gastric cancer (GC) remains a major global health challenge, with rising incidence among patients post- () eradication, particularly those with persistent intestinal metaplasia (IM). Current risk stratification tools are limited in this high-risk population. : To develop, validate, and externally test a machine learning-based prediction model-termed the Early Gastric Cancer Model (EGCM)-for identifying early gastric cancer (EGC) risk in H.
View Article and Find Full Text PDFAssociation between infection of Helicobacter pylori and the risk of reflux oesophagitis occurrence or recurrence: a systematic review and meta-analysis.
eGastroenterology
June 2025
Department of Gastroenterology, The First Affiliated Hospital of Xi'an Medical University, Xi'an, Shaanxi, China.
Background: To investigate the correlation between infection of ) and the risk of reflux oesophagitis (RE) occurrence or recurrence.
Methods: Literature was retrieved from PubMed, Embase, Web of Science and Cochrane Library databases, and the search period ranged from the time of database establishment to December 2024. Prospective cohort studies and randomised controlled trials were included for data analysis to assess the association of infection of with the risk of RE occurrence and recurrence, and subgroup analyses were performed.
Mucosal Atrophy of the Fornix as an Important Endoscopic Finding for an Autoimmune Gastritis Diagnosis.
Intern Med
June 2025
Second Department of Internal Medicine, Shimane University Faculty of Medicine, Japan.
Objective This study investigated the significance of diagnosing an endoscopic atrophic pattern of the fornix in autoimmune gastritis (AIG). Materials Of 10,608 individuals (men/women: 6,551/4,057) who underwent an esophagogastroduodenal endoscopy (EGD) examination between April 2016 and March 2022 for a medical checkup, 80 patients (men/women: 34/46, mean age 58.7 years old) were diagnosed with AIG based on endoscopic findings and positivity for gastric autoantibodies.
View Article and Find Full Text PDFAspirin-Related Chemoprevention of GI Cancers and Bleeding-Related Mortality in Helicobacter Pylori-Eradicated Patients.
Clin Gastroenterol Hepatol
February 2025
Department of Neurology, West China Hospital of Sichuan University, Chengdu, China.
Benefit and Harm of Aspirin on Mortality From Gastrointestinal Cancers Vs Bleeding in Helicobacter pylori-Eradicated Patients.
Clin Gastroenterol Hepatol
September 2024
Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong. Electronic address:
Background & Aims: We investigated the benefit-risk profile of aspirin on mortality reduction from chemoprevention of gastrointestinal (GI) cancer vs excess mortality from bleeding among Helicobacter pylori-eradicated patients, and its interaction with proton pump inhibitors (PPIs).
Methods: H pylori-eradicated patients (between 2003 and 2016), identified from a territory-wide database, were observed from the date of H pylori therapy until death or the end of the study (July 2020). Primary exposure was aspirin use as time-varying variable.